CSL Limited Company Profile (ASX:CSL)

About CSL Limited (ASX:CSL)

CSL Limited logoCSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: ASX:CSL
  • CUSIP: N/A
  • Web: www.csl.com.au/
Average Prices:
  • 50 Day Moving Avg: A$135.23
  • 200 Day Moving Avg: A$124.94
P/E:
  • Trailing P/E Ratio: 43.78
  • P/E Growth: 2.09
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 21.89%
  • Return on Equity: 58.70%
  • Return on Assets: 20.48%
 

Frequently Asked Questions for CSL Limited (ASX:CSL)

What is CSL Limited's stock symbol?

CSL Limited trades on the ASX under the ticker symbol "CSL."

Who are some of CSL Limited's key competitors?

Who are CSL Limited's key executives?

CSL Limited's management team includes the folowing people:

  • Paul Perreault, Chief Executive Officer, Managing Director, Executive Director
  • David Mark Lamont, Chief Financial Officer
  • Gordon Naylor, President - Seqirus
  • Greg Boss, Executive Vice President, Legal and CSL Group General Counsel
  • Karen Etchberger, Executive Vice President - Quality and Business Services
  • Bob Repella, Executive Vice President - Global Commercial Operations
  • Val Romberg, Executive Vice President of Manufacturing and Planning
  • Alan J. Wills, Senior Vice President - Strategy and Business Development
  • Andrew Cuthbertson, Chief Scientific Officer, R&D Director
  • Laurie Cowan, Senior Vice President - Human Resources


MarketBeat Community Rating for CSL Limited (ASX CSL)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about CSL Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CSL Limited (ASX:CSL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for CSL Limited (ASX:CSL)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for CSL Limited (ASX:CSL)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for CSL Limited (ASX:CSL)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for CSL Limited (ASX:CSL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CSL Limited (ASX:CSL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for CSL Limited (ASX:CSL)
Latest Headlines for CSL Limited (ASX:CSL)
Source:
DateHeadline
prnewswire.com logoCSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) - PR Newswire (press release)
www.prnewswire.com - July 22 at 5:21 AM
finance.yahoo.com logoCSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous )
finance.yahoo.com - July 21 at 7:09 PM
prnewswire.com logoVaccines and Influenza Drugs Market to Grow 10.24% CAGR by ... - PR Newswire (press release)
www.prnewswire.com - July 20 at 7:32 PM
finance.yahoo.com logoSeqirus Begins Shipping 2017-2018 Influenza Vaccines to the U.S. Market
finance.yahoo.com - July 20 at 7:32 PM
prnewswire.com logoFDA Accepts CSL Behring's Supplemental Biologics License ... - PR Newswire (press release)
www.prnewswire.com - July 19 at 11:48 PM
finance.yahoo.com logoFDA Accepts CSL Behring's Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication
finance.yahoo.com - July 19 at 6:45 PM
bizjournals.com logoAnti-Infective Vaccines Market at 8.42% CAGR by 2021 Analysis by Disease and Vaccine Type at New Research in ReportsnReports
www.bizjournals.com - July 19 at 12:09 AM
fool.com logo3 small-cap healthcare shares to watch
www.fool.com.au - July 19 at 12:09 AM
fool.com logoStocks to take advantage of a soaring Australian dollar - Motley Fool Australia
www.fool.com.au - July 18 at 7:07 PM
fool.com logoCSL Limited: a standout investment idea for 2018 and beyond
www.fool.com.au - July 14 at 3:22 PM
finance.yahoo.com logoETFs with exposure to CSL Ltd. : July 14, 2017
finance.yahoo.com - July 14 at 3:22 PM
bloomberg.com logoA Cancer Breakthrough Near FDA Approval Has a Costly Side Effect
www.bloomberg.com - July 13 at 4:22 AM
reuters.com logoBRIEF-CSL says new data demonstrate prophylactic treatment with idelvion reduces bleed frequency
www.reuters.com - July 13 at 4:22 AM
fool.com logoAustralian dollar continues to strengthen: Two ways to profit - Motley Fool Australia
www.fool.com.au - July 12 at 11:22 PM
fool.com logoIs CSL Limited back in the buy zone? - Motley Fool Australia
www.fool.com.au - July 12 at 11:22 PM
prnewswire.com logoNew Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to ... - PR Newswire (press release)
www.prnewswire.com - July 12 at 6:19 PM
finance.yahoo.com logoNew Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B
finance.yahoo.com - July 12 at 6:19 PM
fool.com logo3 small-cap shares to watch in FY 2018 - Motley Fool Australia
www.fool.com.au - July 12 at 4:46 AM
fool.com logo5 great ways to blow your huge 2017 bonus - Motley Fool Australia
www.fool.com.au - July 12 at 4:46 AM
prnewswire.com logoCSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders - PR Newswire (press release)
www.prnewswire.com - July 12 at 4:46 AM
finance.yahoo.com logoCSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders
finance.yahoo.com - July 11 at 6:43 PM
reuters.com logoBRIEF-CSL Ltd responds to patent infringement complaint
www.reuters.com - July 10 at 5:34 PM
finance.yahoo.com logoNew Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A
finance.yahoo.com - July 10 at 5:34 PM
finance.yahoo.com logoNew Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017
finance.yahoo.com - July 6 at 6:52 PM
finance.yahoo.com logoCSL Ltd. breached its 50 day moving average in a Bearish Manner : CSL-AU : July 6, 2017
finance.yahoo.com - July 6 at 4:19 AM
reuters.com logoAustralia shares end marginally lower; NZ up
www.reuters.com - June 27 at 3:22 AM
bizjournals.com logoFDA approves CSL Behring therapy for rare disease that can be administered at home
www.bizjournals.com - June 23 at 5:09 PM
finance.yahoo.com logoFDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous ), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema
finance.yahoo.com - June 23 at 5:09 PM
fool.com logoThe CSL Limited share price climbs higher on FDA approval news - Motley Fool Australia
www.fool.com.au - June 23 at 2:54 AM
fool.com logoWhat is The Motley Fool Australia's Extreme Opportunities investing service? - Motley Fool Australia
www.fool.com.au - June 22 at 9:53 PM
finance.yahoo.com logoSeqirus Announces Next Major Advancement in Cell-Based Influenza Vaccine Technology
finance.yahoo.com - June 21 at 5:50 PM
seekingalpha.com logoWeek In Review: IHH Building $1 Billion Of China Hospitals; Seeks Deals For More - Seeking Alpha
seekingalpha.com - June 19 at 2:02 PM
finance.yahoo.com logoETFs with exposure to CSL Ltd. : June 15, 2017
finance.yahoo.com - June 15 at 6:26 PM
fool.com logoCSL Limited taps new all-time high at share price of $142
www.fool.com.au - June 14 at 10:29 PM
fool.com logoCSL Limited share price bounces even higher - Motley Fool Australia
www.fool.com.au - June 14 at 2:10 AM
seekingalpha.com logoCSL (CMXHF) Acquires Wuhan Zhong Yuan Rui De Biological Products - Slideshow
seekingalpha.com - June 13 at 9:09 PM
prnewswire.com logoCSL to acquire majority stake in Chinese plasma fractionator Wuhan Zhong Yuan Rui De Biologicals Products - PR Newswire (press release)
www.prnewswire.com - June 13 at 4:09 PM
finance.yahoo.com logoCSL to acquire majority stake in Chinese plasma fractionator Wuhan Zhong Yuan Rui De Biologicals Products
finance.yahoo.com - June 13 at 12:26 PM
fool.com logoHere’s why I’m so excited about Fisher & Paykel Healthcare Corp Ltd
www.fool.com.au - June 12 at 5:32 PM
fool.com logoWhy these 4 ASX shares stormed higher today | Motley Fool Australia - Motley Fool Australia
www.fool.com.au - June 9 at 7:22 AM
reuters.com logoAustralia shares flat, propped up by GDP data; NZ lower
www.reuters.com - June 7 at 4:34 PM
fool.com logo2 healthcare shares to pounce on at a lower price | Motley Fool ... - Motley Fool Australia
www.fool.com.au - June 2 at 11:02 PM
finance.yahoo.com logoCSL Ltd. – Value Analysis (ASX:CSL) : June 2, 2017
finance.yahoo.com - June 2 at 6:01 PM
reuters.com logoAustralia shares buoyed by defensives while Wesfarmers slides; NZ higher
www.reuters.com - June 1 at 2:37 AM
fool.com logo3 traits I look for in the best ASX shares
www.fool.com.au - June 1 at 2:37 AM
finance.yahoo.com logoCSL Ltd. breached its 50 day moving average in a Bearish Manner : CSL-AU : June 1, 2017
finance.yahoo.com - June 1 at 2:37 AM
finanznachrichten.de logoGlobal Hemophilia Therapeutics Market Outlook 2022 - Anticipated to Witness Moderate Growth - Research and Markets
www.finanznachrichten.de - May 30 at 11:51 AM
bizjournals.com logoInfluenza Vaccines and Drugs Market Growing at a CAGR of 10.24% During 2017 to 2022 Says a Report at ReportsnReports.com
www.bizjournals.com - May 26 at 5:05 PM
fool.com logo3 growth ideas: Buy, Hold, or Sell? - Motley Fool Australia
www.fool.com.au - May 23 at 3:46 PM
fool.com logoHere are 3 fast-growing healthcare shares on my shopping list - Motley Fool Australia
www.fool.com.au - May 23 at 3:46 PM

Social

Social activity is not available for this stock.
This page was last updated on 7/22/2017 by MarketBeat.com Staff